In contrast, finerenone, a non-steroidal mineralocorticoid receptor antagonist, has not only been shown to reduce proteinuria, but also to slow the progression of CKD (stages 3 and 4 with albuminuria) and T2DM [115,116]. Here, NR3C2 is linked to chronic kidney disease.